Focused On-demand Library for RNA-binding protein NOB1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9ULX3

UPID:
NOB1_HUMAN

ALTERNATIVE NAMES:
Phosphorylation regulatory protein HP-10; Protein ART-4

ALTERNATIVE UPACC:
Q9ULX3; Q7L6B7; Q7M4M4; Q7Z4B5; Q9NWB0

BACKGROUND:
The RNA-binding protein NOB1, known for its alternative names Phosphorylation regulatory protein HP-10 and Protein ART-4, is implicated in critical cellular mechanisms. It is probable that NOB1 is involved in mRNA degradation and is required for the processing of 20S pre-rRNA precursor, which is a key step in the formation of 40S ribosomal subunits. This indicates NOB1's significant role in ribosomal assembly and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of RNA-binding protein NOB1 offers a promising avenue for developing novel therapeutic approaches. Given its essential role in the biogenesis of ribosomal subunits and mRNA degradation, targeting NOB1 could provide new strategies for treating conditions associated with ribosomal dysfunction or mRNA processing anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8085 of 8789